John G. Houston Sells 5,405 Shares of Arvinas Inc (NASDAQ:ARVN) Stock

Arvinas Inc (NASDAQ:ARVN) CEO John G. Houston sold 5,405 shares of the business’s stock in a transaction that occurred on Thursday, March 19th. The stock was sold at an average price of $37.61, for a total transaction of $203,282.05. Following the completion of the sale, the chief executive officer now directly owns 815,355 shares of the company’s stock, valued at $30,665,501.55. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link.

ARVN stock opened at $40.82 on Thursday. The business has a 50-day simple moving average of $46.71 and a 200 day simple moving average of $36.47. Arvinas Inc has a 52 week low of $14.06 and a 52 week high of $54.95. The company has a quick ratio of 8.86, a current ratio of 8.86 and a debt-to-equity ratio of 0.02.

Arvinas (NASDAQ:ARVN) last issued its earnings results on Monday, March 16th. The company reported ($0.56) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.54) by ($0.02). Arvinas had a negative return on equity of 30.16% and a negative net margin of 163.56%. The business had revenue of $4.89 million for the quarter, compared to analyst estimates of $4.77 million. As a group, research analysts forecast that Arvinas Inc will post -2.47 EPS for the current fiscal year.

Several analysts recently issued reports on ARVN shares. Cantor Fitzgerald upped their price objective on shares of Arvinas from $42.00 to $75.00 and gave the stock an “overweight” rating in a report on Friday, December 20th. ValuEngine upgraded shares of Arvinas from a “sell” rating to a “hold” rating in a research note on Tuesday. BidaskClub cut shares of Arvinas from a “strong-buy” rating to a “buy” rating in a research note on Friday, March 13th. Piper Jaffray Companies increased their target price on shares of Arvinas from $35.00 to $58.00 and gave the stock an “overweight” rating in a research report on Monday, January 6th. Finally, HC Wainwright initiated coverage on shares of Arvinas in a report on Thursday, December 19th. They set a “buy” rating and a $50.00 price objective on the stock. Two equities research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Arvinas currently has an average rating of “Buy” and an average price target of $49.55.

A number of hedge funds have recently made changes to their positions in the stock. Tower Research Capital LLC TRC bought a new position in shares of Arvinas during the 3rd quarter worth approximately $47,000. State Street Corp boosted its stake in Arvinas by 11.5% in the 3rd quarter. State Street Corp now owns 343,938 shares of the company’s stock worth $7,412,000 after purchasing an additional 35,366 shares during the period. California State Teachers Retirement System boosted its stake in Arvinas by 5.6% in the 3rd quarter. California State Teachers Retirement System now owns 28,596 shares of the company’s stock worth $616,000 after purchasing an additional 1,508 shares during the period. Barclays PLC boosted its position in shares of Arvinas by 578.7% during the 3rd quarter. Barclays PLC now owns 88,820 shares of the company’s stock valued at $1,914,000 after acquiring an additional 75,733 shares during the last quarter. Finally, Kellogg W K Foundation Trust bought a new stake in shares of Arvinas during the 3rd quarter valued at about $252,000. Institutional investors and hedge funds own 77.22% of the company’s stock.

About Arvinas

Arvinas, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER positive/HER2 negative breast cancer.

Featured Story: Is a Roth IRA right for you?

Insider Buying and Selling by Quarter for Arvinas (NASDAQ:ARVN)

Receive News & Ratings for Arvinas Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arvinas and related companies with MarketBeat.com's FREE daily email newsletter.